Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from REGN

3 Blue-Chip Stocks With Strong Buy Ratings

Blue-chip stocks offer stability and consistent growth irrespective of market conditions. Thus, blue chip names Lockheed Martin (LMT), Regeneron Pharmaceuticals (REGN), and Cigna Group (CI) could be prudent additions to your portfolios. These stocks are Strong Buy-rated in our proprietary POWR Ratings system. Read on.

StockNews.com

3 Biotech Stocks With Revolutionary Pipelines to Buy Today

The biotech industry is experiencing rapid growth owing to new drug innovations and advancements in healthcare. To capitalize on the industry's expansion, it could be wise to invest in solid biotech stocks, Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD), which have revolutionary pipelines. Read on….

StockNews.com

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit increase.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Barchart

The biotech industry’s rapid expansion is driven by rising healthcare sending, groundbreaking innovations, and strategic collaborations, propelling the growth of biopharma companies. Thus, it could be wise to invest in popular biotech stocks Illumina (ILMN), Shionogi (SGIOY), and Regeneron Pharmaceuticals (REGN) for substantial gains. Keep reading….

StockNews.com

Plunge into Profits With These 3 Biotech Stocks

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

StockNews.com

4 A-Rated Biotech Stock Picks for 2024 Success

The biotechnology industry is experiencing significant growth, fueled by recent breakthroughs in drug development, technological innovations, and robust government support. Given this backdrop, promising biotech stocks Shionogi & Co. (SGIOY), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and United Therapeutics Corporation (UTHR) could be solid buys for 2024 success. Also, these…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

StockNews.com

Investors Keeping a Close Eye on These 3 Biotech Stocks

Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of personalized medicine are expected to drive growth in the biotech market. Therefore, it could be wise to buy fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Corcept Therapeutics (CORT), and Incyte (INCY). Read more.

StockNews.com

3 Biotechs with Massive Growth Potential

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

StockNews.com

3 Biotech Gainers to Consider

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

StockNews.com

3 Biotech Stocks to Buy for August

The biotechnology sector has experienced extraordinary expansion, largely due to technological advancements that continue to position the industry as a pioneering influencer in crucial areas of healthcare, agriculture, and environmental stability. Given this backdrop, quality biotech stocks Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and United Therapeutics (UTHR) could be solid…

StockNews.com

3 Biotech Stocks With 'A' POWR Ratings

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the adoption of emerging technologies. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and United Therapeutics (UTHR) might be solid buys. These stocks are A (Strong Buy) rated in our proprietary…

StockNews.com

2 Game-Changing Biotech Stocks, 1 to Sell Now

As the biotech industry looks well-positioned for solid growth driven by strong government support and a growing foothold of personalized medicines, it could be wise for investors to buy fundamentally strong biotech stocks Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN). However, fundamentally weak Titan Pharmaceuticals (TTNP) might be best avoided.…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

4 Best Biotech Stocks According to POWR Ratings

Rapid advancements and soaring demand make the biotech sector well-positioned to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stocks Amgen Inc. (AMGN), Regeneron Pharmaceuticals (REGN), United Therapeutics (UTHR), and Vanda Pharmaceuticals (VNDA) with “Strong Buy” ratings could be wise portfolio additions now. Read on….

Barchart

Stocks Set to Open Mixed as Investors Weigh Fed Comments and Economic Outlook, Apple Earnings on Tap

June S&P 500 futures (ESM23) are down -0.04%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.20% this morning after three major U.S. benchmark indices ended the regular session in the red as market participants digested Federal Reserve Chair Jerome Powell’s comments following the central bank’s widely expected 25…

StockNews.com

A Prescription for Success: Check Out This Strong Pharmaceutical Stock This Week

Leading biotech company Regeneron Pharmaceuticals (REGN) has exhibited robust financial growth in recent years. With the biotech industry’s promising prospects, this stock might be a solid portfolio addition now. Read on….

StockNews.com

3 Biotech Stocks to Accumulate During the Bear Market

2022 has been a challenging year for investors due to the combination of inflation and a slowing economy. Biotech stocks could be a place where investors can find outperformance given their low valuations and strong long-term fundamentals. Amgen (AMGN), Corcept Therapeutics (CORT), and Regneron (REGN) are 3 to consider.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Regeneron Pharmaceuticals Unusual Options Activity

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange trades.

Benzinga

Regeneron Pharmaceuticals Whale Trades For October 03

Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Regeneron Pharmaceuticals Whale Trades For September 06

Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

What Are Whales Doing With Regeneron Pharmaceuticals

A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange trades.

StockNews.com

3 Biotech Stocks to Beat the Bear Market

2022 is a challenging year for the market. After battling surging inflation for the first six months, another threat is emerging with rising recession risk. Biotech stocks could be a place where investors can find outperformance given their low valuations and strong long-term fundamentals.

Benzinga

What Are Whales Doing With Regeneron Pharmaceuticals

Benzinga

This Foreboding Sign Looms Over Regeneron Pharmaceuticals's Chart

If history is any guide, there may be trouble ahead for shares of Regeneron Pharmaceuticals (NASDAQ:REGN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

1 2 3 4 5

People

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.